Archemix
closedArchemix, a biotechnology company, develops and commercializes aptamer therapeutics for the treatment of chronic and acute diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD309—464m (Dealroom.co estimates Apr 2004.)
San Francisco California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$51.8m | Series A | ||
$50.0m | Series B | ||
Total Funding | AUD157m |
Recent News about Archemix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.